Agios Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Agios Pharma (AGIO) PT Raised to $89 at Needham & Company
August 2, 2018 11:51 AM EDTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $89.00 (from $86.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Both TIBSOVO and IDHIFA are now approved in relapsed/refractory AML. Agios is focused on moving both drugs into earlier... More
Agios Pharma (AGIO) Tops Q2 EPS by 36c
August 2, 2018 7:02 AM EDTAgios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.19), $0.36 better than the analyst estimate of ($1.55). Revenue for the quarter came in at $40.41 million versus the consensus estimate of $11.28 million.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
... More